MedPath

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Completed
Conditions
Peripheral T-cell Lymphoma
Registration Number
NCT01110733
Lead Sponsor
Acrotech Biopharma Inc.
Brief Summary

Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

Detailed Description

The COMPLETE registry is a prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices. The registry will enroll newly-diagnosed patients with PTCL treated with a variety of regimens. The COMPLETE registry is designed to better understand PTCL patient characteristics, treatments, and outcomes to help design and understand future clinical trials.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
3000
Inclusion Criteria
  • Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL):

    • Aggressive natural killer (NK)-cell leukemia
    • Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
    • Angioimmunoblastic T-cell lymphoma
    • Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)
    • PTCL, not otherwise specified (NOS)
    • T/NK-cell lymphoma, nasal type
    • Enteropathy-type intestinal lymphoma
    • Hepatosplenic T-cell lymphoma
    • Subcutaneous panniculitis T-cell lymphoma
    • Transformed mycosis fungoides (at diagnosis of transformation)
    • T-cell prolymphocytic leukemia (T-PLL)
    • Cutaneous gamma/delta (ฮณ/ฮด) T-cell lymphoma
    • Cutaneous aggressive CD8+ T-cell lymphoma
    • Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm)
    • Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood)
    • Other T-Cell lymphomas that are not listed in the Exclusion Criteria
  • Patient gives written informed consent

Read More
Exclusion Criteria
  • Patient has other T- or NK-cell malignancies including:

    • Precursor T/NK neoplasms
    • T-cell large granular lymphocytic leukemia
    • Mycosis fungoides, other than transformed mycosis fungoides
    • Sรฉzary syndrome
    • Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (68)

City of Hope National Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Duarte, California, United States

Georgetown University

๐Ÿ‡บ๐Ÿ‡ธ

Washington, District of Columbia, United States

Rush University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

University of Chicago Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

UIC Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Boston Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

University of Miami

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

Indiana University Simon Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Indianapolis, Indiana, United States

St. Francis Medical Group Oncology and Hematology Associates

๐Ÿ‡บ๐Ÿ‡ธ

Indianapolis, Indiana, United States

South Texas Oncology and Hematology, P.A.

๐Ÿ‡บ๐Ÿ‡ธ

San Antonio, Texas, United States

Genesis Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Hot Springs, Arkansas, United States

University of Arkansas for Medical Sciences

๐Ÿ‡บ๐Ÿ‡ธ

Little Rock, Arkansas, United States

Arizona Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Tucson, Arizona, United States

UCLA

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Wilshire Oncology Medical Group

๐Ÿ‡บ๐Ÿ‡ธ

La Verne, California, United States

USC & Norris Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Moores Cancer Center UCSD

๐Ÿ‡บ๐Ÿ‡ธ

La Jolla, California, United States

UCLA Olive View Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Sylmar, California, United States

Danbury Hospital Praxair Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Danbury, Connecticut, United States

Washington Cancer Institute at Washington Hospital Center

๐Ÿ‡บ๐Ÿ‡ธ

Washington, District of Columbia, United States

Hematology Oncology Associates

๐Ÿ‡บ๐Ÿ‡ธ

Loxahatchee Groves, Florida, United States

Medical Specialists of the Palm Beaches

๐Ÿ‡บ๐Ÿ‡ธ

Lake Worth, Florida, United States

Coral Springs Oncology

๐Ÿ‡บ๐Ÿ‡ธ

Coral Springs, Florida, United States

Emory University Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Atlanta, Georgia, United States

Medical College of Georgia

๐Ÿ‡บ๐Ÿ‡ธ

Augusta, Georgia, United States

Georgia Cancer Specialists

๐Ÿ‡บ๐Ÿ‡ธ

Atlanta, Georgia, United States

ProMedica

๐Ÿ‡บ๐Ÿ‡ธ

Lambertville, Michigan, United States

Washington University School of Medicine

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis, Missouri, United States

Cancer Institute of New Jersey

๐Ÿ‡บ๐Ÿ‡ธ

New Brunswick, New Jersey, United States

John Theurer Cancer Center at Hackensack University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Hackensack, New Jersey, United States

Overlook Hospital and Morristown Memorial Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Summit, New Jersey, United States

Roswell Park Cancer Institute

๐Ÿ‡บ๐Ÿ‡ธ

Buffalo, New York, United States

Memorial Sloan-Kettering Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

New York University Clinical Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

University of Rochester

๐Ÿ‡บ๐Ÿ‡ธ

Rochester, New York, United States

Carolina Cancer Management, Inc.

๐Ÿ‡บ๐Ÿ‡ธ

Fayetteville, North Carolina, United States

Carolinas Medical Center Northeast

๐Ÿ‡บ๐Ÿ‡ธ

Concord, North Carolina, United States

Community Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Lorain, Ohio, United States

Fox Chase Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Guthrie Clinic, Ltd

๐Ÿ‡บ๐Ÿ‡ธ

Sayre, Pennsylvania, United States

UT Southwestern

๐Ÿ‡บ๐Ÿ‡ธ

Dallas, Texas, United States

Center for Cancer and Blood Disorders

๐Ÿ‡บ๐Ÿ‡ธ

Fort Worth, Texas, United States

JPS Center for Cancer Care

๐Ÿ‡บ๐Ÿ‡ธ

Fort Worth, Texas, United States

University of Virginia Health System

๐Ÿ‡บ๐Ÿ‡ธ

Charlottesville, Virginia, United States

Tyler Hematology Oncology, PA

๐Ÿ‡บ๐Ÿ‡ธ

Tyler, Texas, United States

University of Wisconsin Comprehensive Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Madison, Wisconsin, United States

West Virginia University

๐Ÿ‡บ๐Ÿ‡ธ

Morgantown, West Virginia, United States

Vanderbilt University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Nashville, Tennessee, United States

West Michigan Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Kalamazoo, Michigan, United States

Dartmouth-Hitchcock Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Lebanon, New Hampshire, United States

St. Louis University Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis, Missouri, United States

Louisiana State University Health Science Center (LSUHSC)

๐Ÿ‡บ๐Ÿ‡ธ

Shreveport, Louisiana, United States

University of Maryland

๐Ÿ‡บ๐Ÿ‡ธ

Baltimore, Maryland, United States

Genesys Hurley Cancer Institute

๐Ÿ‡บ๐Ÿ‡ธ

Flint, Michigan, United States

Metro Minnesota Community Clinical Oncology Program

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis Park, Minnesota, United States

Kootenai Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Post Falls, Idaho, United States

John H. Stroger, Jr. Hospital of Cook County

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

University of Tennessee Cancer Institute

๐Ÿ‡บ๐Ÿ‡ธ

Memphis, Tennessee, United States

Michigan State University

๐Ÿ‡บ๐Ÿ‡ธ

East Lansing, Michigan, United States

Simmons Cooper Cancer Institute at SIU School of Medicine

๐Ÿ‡บ๐Ÿ‡ธ

Springfield, Illinois, United States

Moffit Cancer Center

๐Ÿ‡บ๐Ÿ‡ธ

Tampa, Florida, United States

Northwestern University

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Stanford University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Stanford, California, United States

MD Anderson Orlando

๐Ÿ‡บ๐Ÿ‡ธ

Orlando, Florida, United States

Research Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Kansas City, Missouri, United States

Yale University School of Medicine

๐Ÿ‡บ๐Ÿ‡ธ

New Haven, Connecticut, United States

University of North Carolina Chapel Hill

๐Ÿ‡บ๐Ÿ‡ธ

Chapel Hill, North Carolina, United States

DCH Cancer Treatment Center

๐Ÿ‡บ๐Ÿ‡ธ

Tuscaloosa, Alabama, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath